Table 4 Risk factors for CDDP induced nephrotoxicity.

From: Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study

 

Univariate

Multivariate

OR

95%CI

p-value

OR

95%CI

p-value

Sex

 Female vs. male

2.805

1.552–5.069

< 0.001

   

Age (years)

 ≥ 63 vs. < 63

0.849

0.519–1.389

0.515

   

Alb (g/L)

 < 3.9 vs. ≥ 3.9

1.238

0.758–2.024

0.394

   

Cardiac disease

 Yes vs. no

3.239

1.320–7.950

0.010

   

Diabetes

 Yes vs. no

0.756

0.349–1.638

0.479

   

Hypertension

 Yes vs. no

3.158

1.875–5.318

< 0.001

2.430

1.394–4.234

0.017

CDDP dose (mg/m2)

 ≥ 75 vs. < 75

1.596

0.948–2.687

0.079

2.321

1.289–4.181

0.005

Mg supplementation

 No vs. yes

3.615

1.894–6.900

< 0.001

5.420

2.536–11.583

< 0.001

NSAIDs (regular use)

 Yes vs. no

2.632

1.543–4.488

< 0.001

   

Chemotherapy cycle

 3 or more vs. 2 or less

2.297

1.348–3.915

0.002

   

Diuretics

 Mann vs. Furo

4.564

2.590–8.042

< 0.001

4.833

2.665–8.765

< 0.001

  1. Alb, albumin; CDDP, cis-diamminedichloroplatinum (cisplatin); CI, confidence interval; Mg, magnesium; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio.
Back to article page